ПРЕЗЕНТАЦИЯ В КОПЕНГАГЕН

1.

METHOD FOR INCREASING THE ULTRASOUND CONDUCTIVITY OF
CRANIAL BONE TISSUE IN PATIENTS WHO ARE PLANNING FOCUSED
ULTRASOUND TREATMENT UNDER THE CONTROL OF MAGNETIC
RESONANCE IMAGING
Liliya Kuzina*
Background and Objectives
Improvement of cranial bone density for further focused
ultrasound treatment under the control of magnetic
resonance imaging in patients with Parkinson's disease,
dystonia and essential tremor
The objective of the invention is to develop a method for
increasing the ultrasound conductivity of cranial bone tissue
for further surgical interventions in patients using focused
ultrasound under the control of magnetic resonance therapy
in a short time and a safer method.
Table 1
Changes in the ultrasound conduction coefficient of
bone tissue during therapy
full
name
age
gender
coefficient of coefficient of
ultrasound
ultrasound
conduction conduction of
of bone
bone tissue
tissue before after therapy
therapy
Ch.O.G. 61
W
0,34
0,41
S.I.A.
51
M
0,34
0,38
M.E.A.
41
M
0,32
0,41
K.A.M.
54
M
0,32
0,42
B.H.S.
66
M
0,34
0,43
P.A.V.
60
M
0,34
0,42
P.N.M.
68
M
0,32
0,43
Materials and methods
7 patients with motor impairments underwent focused
ultrasound treatment under MRI control using heating or
cavitation at a variable distance from the sensor for
selective thermocoagulation in a well-defined volume. The
bone tissue of the skull affects the distortion of the
trajectory of acoustic waves in the brain.This leads to the
fact that ultrasonic waves do not structurally gather in
focus, changing the shape or location of the focus. It follows
from this that one of the limitations for conducting magnetic
resonance therapy is the density of cranial bone tissue,
which is expressed by the coefficient of ultrasound
conductivity of bone tissue, which should be at least 0.35,
which was studied using computed tomography. To improve
the ultrasound conduction coefficient of cranial bone tissue,
patients were prescribed Bonviva (Ibandronic acid) at a
dose of 3 mg, Aquadetrim (colecalciferol) at a dose of 15006000 units and Calcium D3 Nicomed at a dose of 500 +200
mg (calcium carbonate + colecalciferol). The course of
treatment is 3-6 months. After 3 months, the patients
underwent repeated computed tomography of the skull
bones using the same device to evaluate the effectiveness
of the treatment. When the ultrasound conduction
coefficient of the cranial bone tissue increases by more
than 0.35, the patient is referred for surgery using focused
ultrasound. If there was no effect after 3 months, the
treatment was continued for up to 6 months.
Results
A total of 7 such operations were performed, and each
patient showed positive results after 3 and 6 months, which
were successfully treated with a non-invasive method using
focused ultrasound.
Differences in the coefficient of ultrasound conduction of
bone tissue before and after therapy according to the
proposed method were statistically reliable (Table 2).
Table 2
Average values of bone ultrasound conduction
coefficient before and after therapy
m±s
coefficient of
ultrasound
conduction of bone
tissue before therapy
coefficient of
P
ultrasound
conduction of
bone tissue after
therapy
0,33±0,014
0,41±0,042
<0,0001
Conclusion: Thus, it follows from the presented data
that as a result of the therapy performed according to
the claimed method, it was possible to reach the
threshold value necessary to perform thalamotomy
using focused ultrasound under the control of magnetic
resonance imaging, which contributes to improving the
quality of life of patients with motor disorders in the
shortest possible time.
*This work is an invention and patent has been granted for it. The claimed invention is the subject of patent rights, meets the conditions of
patentability, the essence of the claimed invention is disclosed in the application documents with completeness sufficient for the implementation of
the invention, and therefore a decision was made to grant a patent for the invention dated April 14, 2025. The author of the invention is Kuzina Lilia
Albertovna.